141 related articles for article (PubMed ID: 35249366)
1. Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives.
Amin S; Tolaney SM; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Mulvihill E; Shinde R; McLaurin K
Future Oncol; 2022 May; 18(16):1927-1941. PubMed ID: 35249366
[TBL] [Abstract][Full Text] [Related]
2. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
3. Oncologist and Patient Preferences for Attributes of CDK4/6 Inhibitor Regimens for the Treatment of Advanced/Metastatic HR Positive/HER2 Negative Breast Cancer: Discrete Choice Experiment and Best-Worst Scaling.
Maculaitis MC; Liu X; Will O; Hanson M; McRoy L; Berk A; Crastnopol M
Patient Prefer Adherence; 2020; 14():2201-2214. PubMed ID: 33177814
[TBL] [Abstract][Full Text] [Related]
4. Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Liu FX; Witt EA; Ebbinghaus S; DiBonaventura Beyer G; Shinde R; Basurto E; Joseph RW
Patient Prefer Adherence; 2017; 11():1389-1399. PubMed ID: 28860722
[TBL] [Abstract][Full Text] [Related]
5. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
Mansfield C; Botha W; Vondeling GT; Klein K; Wang K; Singh J; Hackshaw MD
Breast Cancer; 2023 Jan; 30(1):23-35. PubMed ID: 36074320
[TBL] [Abstract][Full Text] [Related]
6. Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment.
Beusterien K; Maculaitis MC; Hallissey B; Gaschler MM; Smith ML; Law EH
Patient Prefer Adherence; 2021; 15():611-623. PubMed ID: 33776424
[TBL] [Abstract][Full Text] [Related]
7. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
[TBL] [Abstract][Full Text] [Related]
8. Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment.
Yong C; Cambron-Mellott MJ; Seal B; Will O; Maculaitis MC; Clapp K; Mulvihill E; Cotarla I; Mehra R
Patient Prefer Adherence; 2022; 16():123-135. PubMed ID: 35068928
[TBL] [Abstract][Full Text] [Related]
9. Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
Grivas P; Veeranki P; Chiu K; Pawar V; Chang J; Bharmal M
Future Oncol; 2023 Feb; 19(5):369-383. PubMed ID: 36876486
[TBL] [Abstract][Full Text] [Related]
10. How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China.
Zhang M; He X; Wu J; Wang X; Jiang Q; Xie F
Value Health; 2022 Oct; 25(10):1768-1777. PubMed ID: 35710892
[TBL] [Abstract][Full Text] [Related]
11. Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2- Advanced Breast Cancer.
Stellato D; Thabane M; Eichten C; Delea TE
Curr Oncol; 2021 Jan; 28(1):491-508. PubMed ID: 33466914
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer.
McQuellon RP; Muss HB; Hoffman SL; Russell G; Craven B; Yellen SB
J Clin Oncol; 1995 Apr; 13(4):858-68. PubMed ID: 7707112
[TBL] [Abstract][Full Text] [Related]
13. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.
Mühlbacher AC; Nübling M
Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856
[TBL] [Abstract][Full Text] [Related]
14. Association between strong patient-oncologist agreement regarding goals of care and aggressive care at end-of-life for patients with advanced cancer.
Douglas SL; Daly BJ; Lipson AR; Blackstone E
Support Care Cancer; 2020 Nov; 28(11):5139-5146. PubMed ID: 32060703
[TBL] [Abstract][Full Text] [Related]
15. Patient preferences for breast cancer treatments: a discrete choice experiment in France, Ireland, Poland and Spain.
Stamuli E; Corry S; Ross D; Konstantopoulou T;
Future Oncol; 2022 Mar; 18(9):1115-1132. PubMed ID: 35043660
[TBL] [Abstract][Full Text] [Related]
16. Oncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects.
Le H; Ryan K; Wahlstrom SK; Maculaitis MC; Will O; Mulvihill E; LeBlanc TW
Patient Prefer Adherence; 2021; 15():99-110. PubMed ID: 33519195
[TBL] [Abstract][Full Text] [Related]
17. Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.
Ivanova J; Hess LM; Garcia-Horton V; Graham S; Liu X; Zhu Y; Nicol S
Patient; 2019 Aug; 12(4):393-404. PubMed ID: 30659513
[TBL] [Abstract][Full Text] [Related]
18. What Is Important When Making Treatment Decisions in Metastatic Breast Cancer? A Qualitative Analysis of Decision-Making in Patients and Oncologists.
Rocque GB; Rasool A; Williams BR; Wallace AS; Niranjan SJ; Halilova KI; Turkman YE; Ingram SA; Williams CP; Forero-Torres A; Smith T; Bhatia S; Knight SJ
Oncologist; 2019 Oct; 24(10):1313-1321. PubMed ID: 30872466
[TBL] [Abstract][Full Text] [Related]
19. Patient Preferences for Pain Management in Advanced Cancer: Results from a Discrete Choice Experiment.
Meads DM; O'Dwyer JL; Hulme CT; Chintakayala P; Vinall-Collier K; Bennett MI
Patient; 2017 Oct; 10(5):643-651. PubMed ID: 28364385
[TBL] [Abstract][Full Text] [Related]
20. Patient preferences do matter: a discrete choice experiment conducted with breast cancer patients in six European countries, with latent class analysis.
Stamuli E; Corry S; Foss P
Int J Technol Assess Health Care; 2023 Apr; 39(1):e21. PubMed ID: 37074007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
